Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

doi:10.1016/S0140-6736(04)16104-7

The Lancet

Volume 363, Issue 9419, 1 May 2004, Pages 1439-1441

https://doi.org/10.1016/S0140-6736(04)16104-7 Get rights and content

Summary

Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo.

References (5)

M Uzunel et al.
The significance of graft-versus-host disease and pretransplant minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
Blood
(2001)
ON Koç et al.
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy
J Clin Oncol
(2000)

There are more references available in the full text version of this article.

Cited by (0)

View full text

Research LettersTreatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Summary

Blood

Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy

J Clin Oncol

Research Letters
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells